Santagostino, who was announced in the role in late October, joined AGC Biologics from the pharmaceutical manufacturing ...

Despite these near-term challenges, we maintain our positive long-term outlook for Lonza thanks to strong demand for outsourced manufacturing of biologics and cell and gene therapies. We maintain ...

Under the terms of the new agreement, Lonza will manufacture the mAb at Lonza’s biologics facility in Porriño (ES), occupying a majority of the site’s manufacturing capacity. The ADC will then be ...

Lonza said it experienced good momentum across the Biologics division with strong commercial demand. Early-stage services continued to recover. In the Small Molecules division, there was continued ...

Lonza LONN-0.93%decrease ... company said its third-quarter performance was driven by solid momentum at its biologics business, partly offset by lower demand in the capsules business due to ...

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores ...

Emerging from the rough waters of the CDMO industry with a new chief executive at the helm, AGC Biologics is on a mission to reinvent itself as a manufacturing partner defined by friendliness and e | ...

We look forward to supporting BigHat with every step in the ADC development and manufacturing process under the Lonza umbrella.” Jean-Christophe Hyvert, President, Biologics, Lonza, added: “We are ...

Under the terms of the new agreement, Lonza will manufacture the mAb at Lonza’s biologics facility in Porriño (ES), occupying a majority of the site’s manufacturing capacity. The ADC will ...

Morgan Stanley analyst Thibault Boutherin has maintained their bullish stance on LONN stock, giving a Buy rating on October 17. Thibault ...